[go: up one dir, main page]

MX2015015249A - Peptidos terapeuticos. - Google Patents

Peptidos terapeuticos.

Info

Publication number
MX2015015249A
MX2015015249A MX2015015249A MX2015015249A MX2015015249A MX 2015015249 A MX2015015249 A MX 2015015249A MX 2015015249 A MX2015015249 A MX 2015015249A MX 2015015249 A MX2015015249 A MX 2015015249A MX 2015015249 A MX2015015249 A MX 2015015249A
Authority
MX
Mexico
Prior art keywords
pyy
therapeutic peptides
novel
analogs
obesity
Prior art date
Application number
MX2015015249A
Other languages
English (en)
Inventor
Steven Thomas Dock
Andrew James Carpenter
Robert Neil Hunter Iii
Yulin Wu
Ved P Srivastava
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2015015249A publication Critical patent/MX2015015249A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)

Abstract

La presente invención se refiere a análogos novedosos de PYY que tienen un perfil terapéutico mejorado cuando se comparan con PYY nativo de humano. Estos análogos de PYY novedosos útiles en el tratamiento de obesidad, diabetes, y otros trastornos.
MX2015015249A 2013-05-02 2014-04-30 Peptidos terapeuticos. MX2015015249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818624P 2013-05-02 2013-05-02
PCT/IB2014/061123 WO2014178018A1 (en) 2013-05-02 2014-04-30 Therapeutic peptides

Publications (1)

Publication Number Publication Date
MX2015015249A true MX2015015249A (es) 2016-02-09

Family

ID=50842285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015249A MX2015015249A (es) 2013-05-02 2014-04-30 Peptidos terapeuticos.

Country Status (20)

Country Link
US (2) US9441023B2 (es)
EP (1) EP2992008B1 (es)
JP (1) JP2016519130A (es)
KR (1) KR20160003848A (es)
CN (1) CN105263957A (es)
AR (1) AR096162A1 (es)
AU (1) AU2014261111B2 (es)
BR (1) BR112015027528B1 (es)
CA (1) CA2909045C (es)
CL (1) CL2015003199A1 (es)
EA (1) EA201591839A1 (es)
ES (1) ES2732291T3 (es)
HK (1) HK1214829A1 (es)
MX (1) MX2015015249A (es)
PE (1) PE20151808A1 (es)
RU (1) RU2015144632A (es)
SG (1) SG11201508469YA (es)
TW (1) TW201534616A (es)
UY (1) UY35548A (es)
WO (1) WO2014178018A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
PE20151808A1 (es) * 2013-05-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Peptidos terapeuticos
RU2671406C2 (ru) 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
WO2016124687A1 (en) * 2015-02-04 2016-08-11 Novo Nordisk A/S Selective pyy compounds and uses thereof
CN107849110B (zh) 2015-06-12 2021-11-26 诺和诺德股份有限公司 选择性pyy化合物及其用途
MX2018008019A (es) 2015-12-28 2018-11-09 Idemitsu Kosan Co Etiqueta de peptido y proteina etiquetada que incluye la misma.
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
EP3592376A1 (en) 2017-03-08 2020-01-15 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TW202535916A (zh) 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
CA3163507A1 (en) * 2019-12-04 2021-06-10 The Scripps Research Institute Peptide conjugates and methods of use
AU2021257477A1 (en) * 2020-04-17 2022-12-08 I2O Therapeutics, Inc. Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
KR20230045088A (ko) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
CN119677527A (zh) 2022-08-18 2025-03-21 勃林格殷格翰国际有限公司 包含长效glp-1/胰高血糖素及npy2受体激动剂的组合疗法
CN117603364A (zh) * 2022-09-30 2024-02-27 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
WO2025217640A1 (en) * 2024-04-12 2025-10-16 Eli Lilly And Company Compositions and methods for treating metabolic diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
PT1019077E (pt) 1997-08-08 2008-02-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
EP1032587B2 (en) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
DE69838916T2 (de) 1997-11-14 2008-12-18 Amylin Pharmaceuticals, Inc., San Diego Neuartige exendin agonisten
CA2320371C (en) 1998-02-13 2012-01-17 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
KR100902625B1 (ko) 2000-08-15 2009-06-15 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 마이크로입자
DE60230818D1 (de) * 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
EP1789440A4 (en) * 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
EP1799241A2 (en) * 2004-09-24 2007-06-27 Merck & Co., Inc. Combination therapy for the treatment of obesity
MX2007006830A (es) 2004-12-13 2008-02-07 Amylin Pharmaceuticals Inc Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
MX2008012221A (es) * 2006-03-23 2009-03-06 Amylin Pharmaceuticals Inc Endotelina y agonistas del receptor de endotelina en el tratamiento de enfermedades metabolicas.
MX2012003939A (es) 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
WO2011050008A2 (en) 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
WO2012006566A2 (en) 2010-07-09 2012-01-12 Amylin Pharmaceuticals, Inc. Microcrystalline y receptor agonists
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
PE20151808A1 (es) * 2013-05-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Peptidos terapeuticos
AU2014350197B2 (en) * 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof

Also Published As

Publication number Publication date
AU2014261111A1 (en) 2015-11-19
ES2732291T3 (es) 2019-11-21
JP2016519130A (ja) 2016-06-30
EP2992008A1 (en) 2016-03-09
US20160108098A1 (en) 2016-04-21
CL2015003199A1 (es) 2016-05-06
CN105263957A (zh) 2016-01-20
RU2015144632A (ru) 2017-06-07
PE20151808A1 (es) 2015-12-16
AR096162A1 (es) 2015-12-09
TW201534616A (zh) 2015-09-16
KR20160003848A (ko) 2016-01-11
CA2909045A1 (en) 2014-11-06
SG11201508469YA (en) 2015-11-27
HK1214829A1 (zh) 2016-08-05
AU2014261111B2 (en) 2017-03-16
US20140329742A1 (en) 2014-11-06
CA2909045C (en) 2022-12-06
US9441023B2 (en) 2016-09-13
WO2014178018A1 (en) 2014-11-06
UY35548A (es) 2014-11-28
BR112015027528B1 (pt) 2023-02-14
EP2992008B1 (en) 2019-04-10
BR112015027528A2 (pt) 2017-12-05
EA201591839A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
MX2015015249A (es) Peptidos terapeuticos.
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2016004907A (es) Analogos del glucagon.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
PH12016500675B1 (en) Acylated glucagon analogues
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
PH12017500296B1 (en) Anti-tigit antibodies
MX2015008114A (es) Derivados de exendina-4.
BR112016023948A2 (pt) proteínas fc multiméricas
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
MX2016010953A (es) Proteinas de fc multimericas.
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
PH12017500032B1 (en) Improved a㟠protofibril binding antibodies
MX2016004325A (es) Nuevo derivado de un analogo de insulina.
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
EA201691567A1 (ru) Способы лечения легких травм головного мозга
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
PH12017501979A1 (en) Pharmaceutical compound
JOP20190101A1 (ar) أنظمة علاج
EA201691220A1 (ru) Способ для получения композиции пегилированных белков
EP3661494B8 (en) Use of tasimelteon for the treatment of affective disorders in majority black african patients